Stay updated on Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Sign up to get notified when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.

Latest updates to the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page
- Check6 days agoChange DetectedAdded the term 'Mucopolysaccharidosis, MPS-II' and removed 'Mucopolysaccharidosis type 2' from the study's glossary/keywords.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed.SummaryDifference0.1%

- Check20 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedRevision: v3.4.2 was added to the page. The funding-lapse/open-status notice and the previous Revision: v3.4.1 entry were removed.SummaryDifference0.5%

- Check56 days agoChange DetectedAdded a site-wide notice about government funding and operating status, and updated the page version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check63 days agoChange DetectedAdded a glossary toggle and new QC/status meta labels (Last Update Submitted that Met QC Criteria and Revision: v3.4.0). Replaced the previous labels Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.